Vuong Trieu - Moderna Chairman of the Board, CFO, Treasurer

MRNA
 Stock
  

USD 159.56  4.02  2.58%   

  Chairman
Dr. Vuong Trieu, Ph.D., is Executive Chairman of the Board, Interim Chief Executive Officer of the Company. Dr. Trieu has served as a director of the Company, and as the Chairman of its Board of Directors, since November 2016. Dr. Trieu currently serves as the Chairman of the Board and the Chief Executive Officer at Autotelic Inc., as the Chairman of the Board and the Chief Regulatory Officer at each of Glucotelic Inc., Osteotelic Inc., Oncotelic Inc. and Stocosil, and as the Chairman of the Board and the Chief Operating Officer at LipoMedics Inc. . He previously served as Chairman of the Board and President of IThenaPharma Inc. from August 2014 until that entitys merger with Marina Biotech in November 2016, as the Chief Scientific Officer of Sorrento Therapeutics, Inc. from September 2013 until May 2014, as the President and Chief Executive Officer at IgDraSol Inc. from January 2012 until August 2013, as the President and Chief Executive Officer at Biomiga Diagnostics from 2011 until August 2013, and as the Director of Biology Pharmacology at Abraxis BioScience from November 2002 until July 2011. He also served as a member of the Board of Directors of Sorrento Therapeutics, Inc. from September 2013 until August 2014
Age: 50  Chairman Since 2018  Ph.D    
617 714-6500  www.modernatx.com
Trieu received a Ph.D. in microbiology / molecular biology from the University of Oklahoma.

Moderna Management Efficiency

Moderna has return on total asset (ROA) of 51.93 % which means that it generated profit of $51.93 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 146.08 %, meaning that it created $146.08 on every $100 dollars invested by stockholders. Moderna management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Investment is expected to grow to 162.97. The current year Return on Average Assets is expected to grow to 0.71. Moderna Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 24.67 Billion. The current year Current Assets is expected to grow to about 17.3 B, whereas Tax Assets are forecasted to decline to about 291.7 M.
The company currently holds 916 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Moderna has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Moderna until it has trouble settling it off, either with new capital or with free cash flow. So, Moderna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moderna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moderna to invest in growth at high rates of return. When we think about Moderna's use of debt, we should always consider it together with cash and equity.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people. Moderna (MRNA) is traded on NASDAQ Exchange in USA. It is located in 200 Technology Square, Cambridge, MA 02139, United States and employs 2,700 people. Moderna is listed under Pharmaceutical Products category by Fama And French industry classification.

Moderna Leadership Team

Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vuong Trieu, Chairman of the Board, CFO, Treasurer
Michael French, Chairman, CEO and Pres
Larn Hwang, Chief Scientific Officer
Daniel Geffken, Interim CFO
Erik Emerson, Chief Commercial Officer
Nancy Phelan, Director
Philip Ranker, Director
Joseph Ramelli, Independent Director
Mihir Munsif, COO
Amit Shah, CFO
Tim Boris, Director
Philippe Calais, Director
Donald Williams, Independent Director
Peter Weinstein, Chief Legal Officer
Stefan Loren, Lead Independent Director
Robert Moscato, CEO
Isaac Blech, Director
Eric Teague, CFO
Uli Hacksell, Chairman of the Board

Moderna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Moderna Investors Sentiment

The influence of Moderna's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moderna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Moderna's public news can be used to forecast risks associated with investment in Moderna. The trend in average sentiment can be used to explain how an investor holding Moderna can time the market purely based on public headlines and social activities around Moderna. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Moderna's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Moderna's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Moderna's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Moderna.

Moderna Implied Volatility

    
  82.42  
Moderna's implied volatility exposes the market's sentiment of Moderna stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Moderna's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Moderna stock will not fluctuate a lot when Moderna's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moderna in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moderna's short interest history, or implied volatility extrapolated from Moderna options trading.

Current Sentiment - MRNA

Moderna Investor Sentiment

Most of Macroaxis users are now bullish on Moderna. What is your trading attitude regarding investing in Moderna? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
61.9 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.